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Abstract
Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes
that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available
therapies, there remains significant morbidity and mortality in this disease. There is great interest in identifying and applying
biomarkers to help diagnose patients with pulmonary arterial hypertension, inform prognosis, guide therapy, and serve as surrogate
endpoints. An extensive literature on potential biomarker candidates is available, but barriers to the implementation of biomarkers
for clinical use in pulmonary arterial hypertension are substantial. Various omic strategies have been undertaken to identify key
pathways regulated in pulmonary arterial hypertension that could serve as biomarkers including genomic, transcriptomic, prote-
omic, and metabolomic approaches. Other biologically relevant components such as circulating cells, microRNAs, exosomes, and
cell-free DNA have recently been gaining attention. Because of the size of the datasets generated by these omic approaches and
their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning. There is growing interest
in imaging the lung with various modalities to understand and visualize processes in the lung that lead to pulmonary vascular
remodeling including high resolution computed tomography, Xenon magnetic resonance imaging, and positron emission tomog-
raphy. Such imaging modalities have the potential to demonstrate disease modification resulting from therapeutic interventions.
Because right ventricular function is a major determinant of prognosis, imaging of the right ventricle with echocardiography or
cardiac magnetic resonance imaging plays an important role in the evaluation of patients and may also be useful in clinical studies of
pulmonary arterial hypertension.
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Introduction
Pulmonary arterial hypertension (PAH) is a pathologically
and clinically heterogeneous group of diseases characterized
by the remodeling of the small pulmonary vasculature and
consequent precapillary pulmonary hypertension. The
pathobiological processes that lead to disease development
are diverse and underpinned by the influence of genetic, bio-
logical, and environmental stimuli. The interaction of ther-
apy with the biological pathways that drive disease and
clinical response to therapy are challenging to assess. As
such, there has been growing interest in the potential role
of biomarkers in the evaluation and treatment of PAH.
An extensive range of biological features at all levels of
cell structure, regulation, and metabolism including genetic
markers, epigenetics, gene expression (RNA), microRNAs
(miRNA), proteins, circulating cell populations, metabol-
ites, cell-free DNA, and exosomes have been studied as
potential biomarkers in PAH. Because lung biopsy is rela-
tively contra-indicated in this patient population, there has
Corresponding author:
Anna Hemnes, Vanderbilt University Medical Center, T1218 MCN 1161 21st
Ave s Nashville, TN 37232, USA.
Email: Anna.r.hemnes@vumc.org
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which per-
mits non-commercial use, reproduction and distribution of the work without further permission provided the original work is
attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).




been strong interest in developing non-invasive imaging
modalities of the lung and, in particular, of the pulmonary
vasculature to provide information about underlying disease
processes in PAH. Right ventricular function has a major
impact on prognosis in PAH; therefore, imaging of the right
ventricle (RV) with echocardiography or cardiac magnetic
resonance imaging (cMRI) may play an important role in
clinical management and the evaluation of efficacy in clinical
trials of PAH. Broadly, the role of biomarkers may be
placed into one or more of the following categories:
1. For diagnosis
2. For prognosis
3. To predict therapeutic response
4. To serve as a surrogate endpoint
There have been extensive explorations of biomarkers for
PAH diagnosis and to a lesser extent prognosis. The reader
is referred to excellent references for consideration of PAH
diagnostic biomarker candidates.1–4 This review will focus
on the potential utility of biomarkers in clinical studies to
signal therapeutic efficacy and the challenges of developing
biomarkers as surrogate endpoints.
Various, and at times Quixotic, attempts have been made
to identify circulating factors that reflect changes in the pul-
monary vasculature during disease progression and under
treatment. In addition, these circulating factors offer mech-
anistic insight into disease pathogenesis. Omic approaches
(genomics, transcriptomics, proteomics, metabolomics, and
volatilomics) to identify panels of biomarkers are increas-
ingly employed to address the complexity of this disease
(Fig. 1).
Advanced information technologies, including artificial
intelligence/machine learning, have been deployed to
identify leitmotifs within complex biological networks
found in PAH blood samples, as well as to decipher non-
intuitive signatures from imaging modalities. In addition to
blood-based biomarkers, emerging technologies show prom-
ise in non-invasive, potentially mechanistic, imaging of the
lung, including three-dimensional reconstructions of the pul-
monary vasculature derived from computed tomographic
(CT) data, Xenon magnetic resonance imaging (MRI) of
the lung, which can evaluate the lung parenchyma and pul-
monary capillary blood flow, and positron emission tomog-
raphy (PET) imaging with tracers that are associated with
altered metabolism (fluorine-18-labeled 2-fluoro-2-deoxy-
glucose (18FDG)), cell proliferation (18FLT), and inflam-
mation (68-Gallium mannosylated albumin) (Fig. 2).
Evaluation of the RV has been gaining increased
attention because of the strong relationship between RV
function and mortality in PAH. The imaging modalities of
the RV of greatest interest are echocardiography and cMRI
(Fig. 2).
The regulatory view of surrogate endpoints
The European Medicines Agency (EMA) has published a
guideline for the use of biomarkers as surrogate endpoints
(EMA Guideline Clinical Trials Small Populations 2006).
The utility of surrogate endpoints was placed in the context
of rare disorders where, for a given clinical endpoint,
recruitment of a sufficient number of patients would be dif-
ficult or demonstration of this clinical endpoint would take
an unreasonable length of time. In that scenario, use of
other surrogate markers as substitutes for a clinical endpoint
may be considered. However, the EMA guideline also
pointed out that the term ‘‘surrogate endpoint’’ should
only be used for biomarkers which have been validated.
Fig. 1. PAH is characterized by an abnormal proliferation of endothelial cells, and myofibroblasts within the pulmonary arterioles as well as
perivascular inflammation that result in muscularization and hypertrophy of the vessel wall. Various ‘‘omic’’ strategies have been taken to decipher
the underlying mechanisms of these pathologic processes.
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Thus, the question arises: what is required to validate a
surrogate endpoint? Looking to the oncology literature,
where such efforts have had a long history, it has been pro-
posed that the coefficient of determination (R2) trial statistic
be used.5 The R2 trial statistic requires a meta-analysis of
multiple clinical trials where each trial serves as one data
point. Linear regression is then performed to compare the
change in the surrogate endpoint vs the change in the
‘‘hard’’ clinical endpoint. Cut-offs are chosen which are
deemed acceptable for regulatory use. For example the
German Institute for Quality and Efficiency in Health
Care; Institut für Qualität und Wirtschaftlichkeit im
Gesundheitswesen has indicated that there is lack of validity
if upper bound of 95% CI R 0.7 (in this case R2¼ 0.49)
and that validity is proven if the lower bound of 95% CI
R 0.85. Thus it is apparent that a ‘‘catch-22’’ emerges
when we try to consider the use of a surrogate endpoint in
lieu of a previously accepted clinical endpoint: the purpose
of the surrogate endpoint is to address the limitations of a
small population with a rare disease and the time it would
take to demonstrate efficacy with clinical endpoints such as
time to clinical worsening. However, to validate the surro-
gate endpoint would require performance of multiple clin-
ical trials, which would obviously take even longer than
performing just one phase 3 trial with a clinical primary
endpoint.
While R2 cut-offs are arbitrary, for most trials in oncol-
ogy, an R2 is not even available. In the oncology space, it
has been noted that of the 25 drugs approved by accelerated
pathway, 84% had no trial-level validation and that poorly
validated surrogates can be misleading.5 With regard to
PAH, there are currently no validated biomarkers. Indeed,
even NT-proBNP, the well-respected biomarker for heart
failure, has not been validated.
Based on these criteria, there is currently no biomarker in
PAH that is a surrogate endpoint. Nevertheless, biomarkers
that predict therapeutic response or track such response,
especially early in treatment, may still have utility to guide
clinical study design and development of therapeutic targets.
Furthermore, newer endpoints, such as measures of ambu-
latory activity, are being viewed favorably and may not
require this level of validation.
Genetics of PAH
Much progress has been made over the last several decades
in the understanding of genetic risk for PAH. After the ini-
tial discovery that mutations in the bone morphogenetic
receptor type 2 (BMPR2) underlie approximately 80% of
heritable PAH (hPAH),6,7 there was a rapid appreciation
that this mutation is incompletely penetrant and that
about 10–15% of patients with idiopathic PAH (IPAH)
also carry mutation in BMPR2.8 These data suggest that
either there is a low penetrance or under-recognized disease
within some families or that de novo mutations occur in
IPAH patients with BMPR2 mutation and no family history
of the disease. After expanding studies to related genes in
transforming growth factor (TGF)-beta signaling, e.g.
ALK19,10 and endoglin,11 in the late 1990s and early 2000s,
genetic discoveries in PAH were limited by technology and
the low prevalence of the disease, which limited traditional
approaches to the identification of gene mutations asso-
ciated with this disease. With the advent of next generation
sequencing techniques, there has been rapid growth in iden-
tification of genes that appear to associate with and contrib-
ute to PAH in both IPAH and hPAH. These include
CAV1,12 KCNK3,13 GDF2,14 SOX17,15 and TBX416





CT:  3D reconstrucon pulmonary vasculature
Xenon MRI: Pulmonary capillary flow
PET:  Metabolism, proliferaon, inflammaon  
Echo:  RV dimensions; doppler indices, strain
Cardiac MRI: RV dimensions and funcon
Fig. 2. Imaging modalities of the lung include CT, Xenon MRI, and positron emission tomography (PET). Echocardiography and Cardiac MRI are
useful in examining right ventricular dimensions and function in PAH.
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of pulmonary vascular disease (PVD), such as EKFKA24
that underlie pulmonary veno-occlusive disease
(PVOD).17,18 Moreover, PAH with known gene mutations
appears to have a more advanced phenotype. hPAH with
BMPR2 mutation presents at a younger age with more
severe hemodynamics than other forms of PAH19 and is
also associated with worse survival and more severe right
ventricular dysfunction.20
Despite this expansion in understanding genetic under-
pinnings of PAH and how heritable forms of PAH may
affect outcomes, there has been relatively little study of
gene variants that predict drug responses to PAH therapies,
which would be a highly useful property of biomarkers in
this deadly disease. Benza and colleagues demonstrated that
variants in endothelin metabolism may predict outcomes in
PAH patients treated with endothelin receptor antagon-
ists.21 It is presently unknown if any of the recently identi-
fied gene mutations in hPAH and IPAH may influence
likelihood of drug responses in PAH, but this association
has not previously been identified. It is possible that a single
gene may not adequately predict treatment responses and a
combination of genes may be required—or even a combin-
ation of genes with another protein or metabolomic bio-
marker. In prior whole exome testing, the hypothesis was
generated that there is a genetic signature of vasodilator-
responsive (VR)-IPAH which responds to calcium channel
blocker therapy. Vascular smooth muscle contraction-
related genes were found to be enriched in VR-IPAH, sug-
gesting a potentially different genetic predisposition for this
PAH subtype.22 Gene-based biomarkers of drug responsive-
ness are highly attractive, despite their limited study thus
far. However, as DNA is stable over time and not influenced
by the environment or drug exposure, it is well suited to use
as a predictor of drug responses in patients regardless of
their prior treatment course.
Single component biomarker candidates
An extensive list of single biomarker candidates for diagno-
sis and, to a lesser extent, prognosis may be found in the
literature. The most well-known biomarker which reflects
the degree of right ventricular failure in PAH is NT-
proBNP. Reported candidates as diagnostic and/or
prognostic biomarkers for PAH include cytokines such as
interleukin (IL)-1, IL-2, IL-4, IL-6, IL-8, IL-10, tumor
necrosis factor (TNF)-alpha, growth factors, such as vascu-
lar endothelial growth factors (VEGFs), platelet-derived
growth factors (PDGFs), and TGF-beta, CC family chemo-
kines, osteopontin, angiopoietins, matrix metalloprotei-
nases, cardiac troponins, C reactive protein, von
Willebrand factor (vWF), high density lipoprotein (HDL),
thromboxane B2, fibrinogen, soluble fms-like tyrosine
kinase-1 (sFLT1), placental growth factor, lymphotoxin-
like inducible protein that competes with glycoprotein D
for herpesvirus entry on T-lymphocytes (LIGHT), asymmet-
ric dimethylarginine, GDF15, and hepatocyte growth factor
(HDGF) among others.23–34 There is fairly extensive
literature suggesting the potential utility of GDF15 as a bio-
marker for PAH.25,26,29,30,32,35,36 HDGF has also been
reported as informative of prognosis above and beyond
that provided by NT-proBNP.33 None of these biomarkers,
however, meet the criteria for use as a surrogate endpoint.
NT-proBNP is the only circulating biomarker currently
employed in guidelines for risk assessment and is discussed
in more detail below.37
NT-proBNP
NT-proBNP levels have been shown to correlate with car-
diopulmonary hemodynamics, PaO2 at peak exercise, and
peak minute ventilation.38 NT-proBNP has been shown to
reflect changes in cMRI measured RV structure and func-
tion in PAH.39 The 2015 ESC/ERS guidelines indicate that
an NT-proBNP level> 1400 ng/L is associated, among other
parameters, with an increased risk of mortality in PAH.37
In the SERAPHIN hemodynamic substudy, macitentan
improved NT-proBNP compared to placebo at six
months. Absolute levels of NT-proBNP, but not their
changes at baseline and six months, were associated with
morbidity/mortality events.40 In the phase 3 GRIPHON
study, NT-proBNP categories (low, medium, and high
based on ESC/ERS 2015 guideline cut-offs) were prognostic
for future morbidity/mortality events. In a time-dependent
analysis, the risk of a morbidity/mortality event was 92%
lower in the selexipag-treated group, and 90% lower in the
placebo-treated group if the NT-proBNP level was low at
baseline or follow-up.41 In the phase 3 study of imatinib in
PAH, at week 24, NT-proBNP was lower in the imatinib
group compared to placebo.42
Multiplex biomarker candidates
Given the limitations of single biomarkers in risk stratifica-
tion and therapeutic response, there has been a growing
interest in evaluating the utility of multiplex assays. The
advent of advanced high throughput assay technologies
has led to the omic approach at multiple levels of cellular
structure and function as well as various strategies to make
sense of the large resulting datasets, such as network ana-
lysis. Perhaps ironically, many such omic approaches
attempt to whittle down the data to one or two candidates
which are then subjected to more traditional and somewhat
simplistic mechanistic studies. In recognition of this irony,
mathematical modeling of complex systems, including
machine learning, may be rising to the occasion. In some
cases, omic approaches have focused on PAH lung tissue
available at the time of transplant. Analyses are undertaken
with cells obtained from PAH tissues (i.e. human pulmonary
artery smooth muscle cells (HPASMCs)) grown in culture
and other analyses have been performed on circulating cells
or serum/plasma. Because there is particular interest in the
ability to obtain biomarkers in the setting of clinical trials,
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this review will attempt to introduce a discussion about
which pathways regulated in lung tissue or lung-specific
cells from PAH patients intersect or overlap with pathways
similarly regulated in circulating cells, serum, or plasma.
A limitation of lung tissue analysis is that it represents
end-stage disease because the tissue is typically obtained at
the time of lung transplantation (as lung biopsies are not
usually performed in this patient population). Thus, we can
ask, is it reasonable and possible to examine the targets
identified in samples from end-stage disease lungs earlier
in the course of the disease by examining changes in circu-
lating cells, serum, or plasma? This approach can be prob-
lematic because of the different tissue compartments under
study and because the time profile of changes may not vary
in a linear or monotonic manner. In this context, we review
here some examples of currently available high throughput
analyses at the level of gene, miRNA, and protein expres-
sion and some initial attempts to make sense of the data
with a machine learning approach.
Transcriptomics
Gene expression
Several transcriptomic analyses related to PAH have been
performed ranging from comparative studies to whole lung
cell culture-based and, most recently, to single cell RNA
sequencing approaches.
Sasagawa et al.43 performed a comparative transcrip-
tome analysis of five mammalian datasets and identified
228 differentially expressed genes (DEGS) from the
SU5416/hypoxia rat model, 379 DEGS from a mouse
model of PAH associated with systemic sclerosis, 850
DEGS from a mouse PAH model associated with schisto-
somiasis, 1598 DEGS from one cohort of PAH subjects,
and 4269 DEGS from a second cohort of PAH subjects.
Comparative analysis identified four genes that were up-
or downregulated across all the animal models and PAH
patients: coiled-coil domain containing 80 (CCDC80) and
anterior gradient were increased, and SMAD6 and gran-
zyme A were decreased. Knockout of CCDC80 in
Zebrafish showed the role of this gene in vascular devel-
opment. A limitation of this study is the assumption that
common variance across multiple animal models is neces-
sary or sufficient to establish pathological importance in
the human disease.
Stearman et al.44 performed a system analysis of the
human PAH lung transcriptome. Pathway analysis was per-
formed with Enrichr, Gene Ontology, and KEGG. Ingenuity
Pathway Analysis (IPA) was used to visualize pathway over-
representation. In addition, a novel network-based computa-
tional analysis, Evaluation of Differential DependencY
(EDDY), was employed. IPA showed important roles for
Estrogen Receptor 1, TNF, colony-stimulating factor 3,
and IL-10. EDDY analysis demonstrated substantial rewiring
across multiple reactomes. For example, EDDY identified
TLR3 and TLR4 as central to the REACTOME pathway
describing IFN regulatory factors-3 and 7.
In a search for circulating biomarkers, Grigoryev et al.45
sought to identify scleroderma PAH-associated genes regu-
lated in PBMCs. Transcriptomics of PMBCs from IPAH
patients were highly comparable with PBMCs from PAH-
SSC patients. Gene ontology analysis showed significant
changes in genes associated with angiogenesis, such as
MMP9 and VEGF, according to the severity of PAH (per-
haps counterintuitively higher in mild PAH compared to
severe PAH). Other identified regulated genes included
ADM, IL7R, ZFP36, GLUL, JUND, BCL6, adrenomedul-
lin, and herpesvirus entry mediator genes. Novel genes, not
previously associated with PAH, were also reported, such as
EREG, CXCL2, and MMP25.
A meta-analysis of genome-wide expression profiling in
the blood from PAH subjects was performed by Elinoff
et al.46 The comparability of data across seven studies
(which together included 156 PAH patients/110 healthy con-
trols) was assessed and an attempt was made to derive a
generalizable transcriptomic signature. IPAH compared
with disease-associated PAH (APAH) displayed highly simi-
lar expression profiles with no DEGS between the two
groups, even after substantially relaxing selection strin-
gency. In contrast, using a false discovery rate I2 of 1%
and <40% (low-to-moderate heterogeneity across studies),
both IPAH and APAH differed markedly from healthy
controls with the combined PAH cohort yielding 1269 dif-
ferentially expressed, unique gene transcripts. Bioinformatic
analyses, including gene-set enrichment which used all avail-
able data independent of gene selection thresholds, identi-
fied interferon, mammalian target of rapamycin/p70S6K,
stress kinase, and Toll-like receptor signaling as enriched
within the PAH gene signature. Enriched biological func-
tions included tumorigenesis, autoimmunity, antiviral
response, and cell death consistent with prevailing theories
of PAH pathogenesis. Although otherwise indistinguishable,
APAH (predominantly PAH due to systemic sclerosis) had a
somewhat stronger interferon profile than IPAH.
Cheong et al.47 examined the effect of tadalafil on gene
expression profiles in SSC-associated PAH. These authors
found that genes associated with IL-12 and maintenance of
the extracellular matrix were affected by treatment. In add-
ition, genes encoding voltage-gated potassium channels and
genes related to innate immunity were coordinately upregu-
lated in subjects who improved with tadalafil treatment
compared to those who did not. In contrast, upregulation
of Golgi-related gene sets was associated with clinical wor-
sening during the treatment period.
The results of a whole blood RNA sequencing effort in
PAH, which corrected for variance of total cell populations
in samples, found enrichment in T cell receptor, PI3K sig-
naling in B cells, and hypoxia signaling in PAH compared to
controls.48 Specific targets that were differentially regulated
included zinc finger transcription factors (TFs), HIF1-alpha,
KLF10, TRPC1, Sestrin 1, and SMAD5. A Mendelian
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randomization exercise demonstrated the biological rele-
vance of SMAD5 levels in the PAH population. An RNA
LASSO model consisting of 25 genes was found to predict
survival in PAH; 372 of the 507 top dysregulated genes from
the whole blood RNAseq study were present in the lung
tissue microarray study44 and 161/372 (43%) were also dir-
ectionally consistent; 41/161 (25%) genes were nominally
significant and 26 met false discovery rate (FDR) corrected
significance. Sadly, only one gene was found to be similarly
dysregulated in PAH patients in the whole blood RNA
study, the lung transcriptomic study, and the genome-wide
expression meta-analysis: AMD1 (encoding apolyamine
biosynthesis intermediate enzyme, adenosylmethionine
decarboxylase 1), which was consistently lower in PAH
across all three studies.44,46,48
Recently Saygin et al.49 used single cell RNA sequencing
in cells isolated from IPAH lungs to examine differential
gene expression compared to control lungs.
Transcriptomics were determined for endothelial cells,
pericytes/smooth muscle cells, fibroblasts, and macrophage
clusters. Gene ontology enrichments were determined.
Interestingly, in genes associated with blood vessel and
cardiovascular development, PDGF-beta was the most
upregulated gene. PDGF was shown to be increased in
PAH in a biomarker study of the effects of IV treprostinil,
but more recently circulating PDGF levels were not found
to be increased in an observational study, thus highlighting
the potential difficulty of correlating local tissue specific
regulation of PDGF signaling in PAH with peripheral
biomarkers.50,51
Are there any ‘‘take home’’ messages from these recent
transcriptomic efforts? One message seems to be that there is
a connection between lung transcriptomics from PAH
patients and peripheral blood mononuclear cells (PBMCs)
in the circulation. For example, a PBMC regulatory net-
work, identified using the Ingenuity program by Elinoff
et al.,46 showed that TNF-alpha and granulocyte macro-
phage colony stimulating factor (GM-CSF) were signifi-
cantly enriched upstream regulators. Similarly Stearman
et al.44 identified a key role for TNF and CSF3 signaling
in their lung transcriptomic analyses. Additional pathways
identified in both the meta-analysis of PBMCs/blood, per-
formed by Elinoff et al.,46 and the lung transcriptome ana-
lysis, performed by Stearman et al.,44 identified interferon
and toll-like receptor (TLR) pathways as potentially import-
ant. However, when overlap was sought between the recent
whole blood RNA sequencing effort of Rhodes et al.,48 the
prior gene expression meta-analysis of Elinoff et al.,46 and
the lung transcriptomic effort of Stearman et al.,44 there was
only one target that was commonly dysregulated across all
three studies. But do not be disheartened: it is likely that
pathway regulation across these multiple studies may be
more informative than identification of particular targets.
For example, all three studies found differential regulation
of Toll-like receptors which have been implicated in PAH
pathobiology.52,53 Therapeutic or disease-monitoring
strategies based on the networks, pathways, and gene prod-
ucts identified by these studies could be useful in future drug
development for PAH.
The recent report of transcriptomics using single cell
RNA sequencing demonstrated a marked upregulation of
PDGF-BB in genes associated with blood vessel and cardio-
vascular development. This approach suggests an important
role of cell-specific and localized pulmonary regulation that
could be missed by less precise methods. Notably, imatinib,
a kinase inhibitor with PDGFR activity, was shown to be
effective in a phase 3 trial of PAH.54 Although further devel-
opment of orally administered imatinib was hampered by a
number of systemic side effects, there remains on-going
interest in targeting this pathway.
MiRNAs
miRNAs are short noncoding RNAs that regulate gene
expression by inhibiting translation or promoting degrad-
ation of target miRNAs. miRNAs are key regulators of a
wide range of cellular processes and their discovery has
generated a fair amount of interest in their potential role
in PAH disease pathogenesis and/or progression.55,56 A var-
iety of miRNAs have been associated with BMPR2 expres-
sion and signaling in pulmonary vascular cells in vitro and
in vivo. Multiple miRNAs that directly regulate BMPR2
include the miR-17/92cluster, miR-302-367 cluster, and
miR-21.56,57 The large number of miRNAs implicated in
PAH at first glance appear to be a quagmire, but these
can be organized into hierarchical motifs with convergent
and divergent functions.56
Taking a multiomics approach, Chen et al.58 examined
the effect of PDGF-BB on the pulmonary artery smooth
muscle cell (PASMC) transcriptome and proteome. TF-
target network analysis revealed that PDGF-BB regulated
gene expression potentially via TFs including HIF1A, JUN,
EST1, ETS1, SMAD1, FOS, SP1, STAT1, LEF1, and
CEBPB. Notably, PDGF-BB led to BMPR2 downregula-
tion. To understand the mechanism by which this crosstalk
occurred, 1078 miRNAs were examined. It was found that
13 miRNAs changed in a time-dependent manner in
PASMCs treated with PDGF-BB. Using the online predic-
tion tool, Targetscan, multiple binding sites of miR-7,
miR-245, and miR376b were found in the BMPR2
3’UTR. Western blot analysis showed that only miR-376b
could decrease BMPR2 protein levels. An EdU incorpor-
ation assay showed that miR-376b promoted proliferation
of PASMCs. Qian et al.59 found that miR-4632 was highly
expressed in HPASMCs and significantly downregulated
in PDGF-BB-stimulated HPASMCs. Functional studies
revealed that miR-4632 inhibited proliferation and pro-
moted apoptosis of HPASMCs. cJUN was identified as a
direct target gene of miR-4632, and knockdown of cJUN
was necessary for miR-4632-mediated HPASMC prolifer-
ation and apoptosis. In addition, the downregulation of
miR-4632 by PDGF-BB was found to associate with histone
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deacetylation through the activation of PDGF receptor/
phosphatidylinositol 3’-kinase/histone deacetylase 4 signal-
ing. The expression of miR-4632 was reduced in the serum
of patients with PAH. Another miRNA, miR-328, was also
found to mediate PDGF-BB effects in PASMCs.60 In this
study, the expression profiling of 1078 miRNAs was inves-
tigated in PASMCs with or without PDGF-BB stimulation.
MiR-328 was found as a prominent downregulated miRNA,
displaying a specific dose- and time-dependent downregula-
tion upon PDGF-BB exposure. Functional analyses
revealed that miR-328 could inhibit PASMCs proliferation
and migration both with and without PDGF-BB treatment
and the Ser/Thr-protein kinase-1 (PIM-1) was identified as a
direct target of miR-328.
Rothman et al.61 identified a reduction in the levels of
miR-140-5p in subjects with PAH compared to controls.
Inhibition of miR-140-5p promoted PASMC proliferation
and migration in vitro. In rat models of PAH, nebulized
delivery of miR-140-5p mimic prevented the development
of PAH and attenuated the progression of established
PAH. Network and pathway analysis identified SMAD-
specific E3 ubiquitin protein ligase 1 as a key miR-140-5p
target and regulator of BMP signaling as well as with
PDGFR-alpha.
It is apparent that the regulation of miRNAs in PAH is
quite complex with a high level of redundancy. This level of
complexity could represent a challenge to their utility as
biomarkers in future studies. However, of particular interest
are miRNAs that appear to play a role in the regulation of
PDGF signaling and cross talk with the BMPR2 pathway.
Proteomics
Several proteomic analyses have been undertaken to identify
novel biomarkers with potential diagnostic and/or prognos-
tic utility.
In a plasma proteome analysis, Rhodes et al.62 identified
a panel of nine proteins (ILR4, Epo, Factor D, IGFBP-1,
TIMP2, TIMP1, Factor H, Plasminogen, and ApoE) that
provided prognostic information independent of NT-
proBNP levels and the REVEAL equation. The proteins
were related to myocardial stress, inflammation, pulmonary
vascular cellular dysfunction, iron status, and coagulation.
Poor survival was preceded by a change in panel score and
was validated in a follow-up cohort.
Lavoie et al.63 performed a proteomic analysis of out-
growth EPCs from PAH subjects with BMPR2 mutations
compared to controls; 416 proteins were detected with two-
dimensional PAGE in combination with liquid chromatog-
raphy/tandem mass spectrometry analysis, of which 22
exhibited significantly altered abundance in blood-out-
growth ECs from patients with hPAH. One of these pro-
teins, translationally controlled tumor protein (TCTP),
was selected for further study because of its well-established
role in promoting tumor cell growth and survival.
Immunostaining showed marked upregulation of TCTP in
lungs from patients with hPAH and IPAH, associated with
remodeled vessels of complex lesions. Increased TCTP
expression was also evident in the SU5416 rat model of
severe and irreversible PAH, associated with intimal lesions,
co-localizing with proliferating ECs and the adventitia
of remodeled vessels but not in the vascular media.
Furthermore, silencing of TCTP expression increased apop-
tosis and abrogated the hyperproliferative phenotype of
blood-outgrowth ECs from patients with hPAH, raising
the possibility that TCTP may be a link in the emergence
of apoptosis-resistant, hyperproliferative vascular cells after
EC apoptosis.
Meyrick et al.64 performed a proteomic analysis of
transformed lymphocytes obtained from subjects with
familial PAH (FPAH). The transformed blood lympho-
cyte protein extracts from four patients with FPAH,
three obligate carriers, and three married-in control sub-
jects from one family with a known BMPR2 mutation
(exon 3 T354G) were labeled with either Cy3 or Cy5.
Cy3/5 pairs were separated by standard two-dimensional
differential gel electrophoresis using a Cy2-labeled internal
standard of all patient samples. Log volume ratios were
analyzed using a linear mixed-effects model. Proteins were
identified by matrix-assisted laser desorption ionization,
time-of-flight mass spectrometry (TOF MS) and tandem
TOF/TOF MS/MS. Hierarchical clustering, heat-map,
and principal components analyses revealed marked
changes in protein expression in patients with FPAH
when compared with obligate carriers. Significant changes
were apparent in expression of 16 proteins (p< 0.05) when
affected patients were compared with obligates: nine
showed a significant increase and seven showed a signifi-
cant reduction. These proteins could, potentially, have
utility in predicting or tracking response to therapies in
patients with PAH and BMPR2 mutations.
To understand the nature of insulin resistance often
observed in PAH patients, Hemnes et al.65 performed an
aptamer-based proteomic assay to measure abundance of
1139 proteins in fasting plasma from PAH patients and con-
trols. By principal component analysis, PAH patients and
controls were broadly separated by their plasma proteome.
Forty different metabolic pathway proteins were examined
for differential expression between PAH and control and it
was found that 11 were different, at p< 0.05 by unpaired
t test (FDR¼ 2). These differentially expressed proteins
showed significant differences in insulin signaling
(IGFBP6, IGF2R, IGFBP7, IGFBP2, pRKAA1, and
ANGPTL4) and lipid signaling and transport (OLR1,
APOA1, and CD36).
Proteomic analyses show promise to identify subsets of
proteins that may provide prognostic information, identify
the best candidates for particular indications, and predict
response to therapeutic interventions. However, more rigor-
ous efforts in multi-center studies may be needed to further
qualify the use of particular proteins as biomarkers that
could predict response to therapies.
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Metabolomics
Altered mitochondrial and cellular metabolisms have been
well studied and are reviewed elsewhere.66,67 In short, there
are multiple pathways that are affected including, among
others, glucose oxidation, fatty acid oxidation, and glutam-
ine metabolism. These pathways are altered in multiple tis-
sues in PAH including the pulmonary vasculature and
the RV. Given the broad disturbance in metabolism in
PAH and the ready capacity to measure metabolites using
mass-spectroscopy-based techniques, there is interest in
using metabolomics as biomarkers of disease responsive-
ness. There is now evidence that metabolomics may be
useful for this purpose based on the work of Rhodes and
colleagues68 where, after identification of several metabolites
that were different in PAH patients and healthy and con-
trols, the authors found several metabolites in key path-
ways, including tRNA-specific modified nucleosides,
tricarboxylic acid (TCA) intermediaries, glutamate, and
fatty acid acylcarnitines among others, that correlated
with increased risk of death. Importantly, the authors
found that correction of several metabolites over time was
associated with a better outcome in their PAH cohorts.
These data provide a strong justification of using changes
in plasma metabolites over time to identify drug respon-
ders. Integrating a proteomic and phosphoproteomic ana-
lysis of PAH endothelial cells, Xu et al.69 identified
dysregulated pathways in PAH, including accelerated
one carbon metabolism, abnormal TCA cycle flux and glu-
tamate metabolism, dysfunctional arginine and nitric
oxide pathways, and increased oxidative stress.
Functional studies in cells confirmed abnormalities in glu-
cose metabolism, mitochondrial oxygen consumption, and
production of reactive oxygen species in PAH. Thus far,
there have not been studies of which metabolites may pre-
dict responsiveness to a particular drug. Other studies
have used a more reductionist approach, e.g. studying
nitric oxide metabolites in prediction of response to
either phosphodiesterase type 5 inhibitors or soluble gua-
nylate cyclase stimulators. Changes to—and improve-
ments in—metabolism may be detected in the blood, but
there have also been studies demonstrating the feasibility
of using exhaled breath, the so-called ‘‘volatome’’, to dis-
tinguish PAH from control and may be useful for detect-
ing responses to therapy.70 Blood-based or other
metabolites may be early and sensitive markers of changes
in signaling pathways that are relevant to PAH and
affected by drug therapies. There are readily available
mass screening assays to measure hundreds to thousands
of metabolites for low cost compared to many omic ana-
lyses, making their study cost efficient and powerful.
In summary, use of metabolomic assays, both at baseline
and after therapy, may offer the potential to identify markers
of prognostic value at baseline and/or that are sensitive to
change over the course of treatment. It is possible that
changes in metabolites that correlate with important long-
term outcomes could presage other pathophysiologic changes.
Circulating cells in PAH
Circulating mononuclear cells may play an important role for
the vascular remodeling in PAH. Foris et al.71 used a compre-
hensive fluorescence-activated cell sorting analysis of circulating
mononuclear cells in 20 PAH patients and 20 age-and-sex-
matched controls, and additionally analyzed CD133(þ) cells
in the lung tissue of five PAH transplant recipients and five
healthy controls (donor lungs). PAH patients were character-
ized by increased numbers of circulating CD133(þ) cells and
lymphopenia as compared with control. In PAH, CD133(þ)
subpopulations positive for CD117 or CD45 were significantly
increased, whereas CD133(þ) CD309(þ), CD133(þ)
CXCR2(þ), and CD133(þ) CD31(þ) cells were decreased.
In CD133(þ) cells, SOX2, Nanog, Ki67, and CXCR4 were
not detected, but Oct3/4 mRNA was present in both PAH
and controls. In lung tissue, CD133(þ) cells included three
main populations: type 2 pneumocytes, monocytes, and undif-
ferentiated cells without significant differences between PAH
and controls. The authors concluded that circulating
CD133(þ) progenitor cells were elevated in PAH and consisted
of phenotypically different subpopulations that may be up- or
downregulated. CD133(þ) type 2 pneumocytes in the lung
tissue were not associated with circulating CD133(þ) mono-
nuclear cells.
In a series that included 70 patients with pulmonary
hypertension of various etiologies, a significant decrease in
the relative numbers of circulating myeloid dendritic cells,
but not plasmacytoid dendritic cells DCs, was found com-
pared to the healthy controls. Flow cytometric analyses did
not show significant changes between the relative number of
circulating Tregs in patients with PH compared to healthy
controls.72 In a study of circulating cells in PAH patients,
significantly fewer CD8þ T cells but more CD25hiþ and
FoxP3þCD4þ T cells were found in the peripheral blood
of patients compared with controls. The percentage of
FoxP3þ cells within the CD25hiþCD4þ T(reg) cells was
similar. T(reg) cell functionality was equal in patients and
controls.73 An increased CD4:CD8 ratio and deficiencies of
NK cells and cytotoxic CD8þ T-lymphocytes were reported
to be associated with increased one year mortality in PAH.74
In another series, IPAH patients were found to have
abnormal circulating CD8þ T lymphocyte subsets, with a
significant increase in CD45RAþ CCR7– peripheral cyto-
toxic effector-memory cells and reduction of CD45RAþ
CCR7þ naive CD8þ cells versus controls. Furthermore,
IPAH patients had a higher proportion of circulating regu-
latory T cells (T(reg)) and four-fold increases in the number
of CD3þ and CD8þ cells in the peripheral lung compared
with controls.75 CD45RA is a protein tyrosine phosphatase
and is believed to be a marker for T-lymphocytes with
greater cytolytic activity and greater propensity to travel
to non-lymphoid tissues.75
In summary, studies of circulating cells in PAH are inter-
esting, and elegant, but complex and have shown varying
results. The reproducibility and implementation for multi-
center studies to examine their potential role as biomarkers
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to predict therapeutic response may be challenging for both
technical and operational reasons.
Exosomes and cell free DNA
There has been growing interest in the study of exosomes in
PAH. Exosomes are nano-sized (30–150nm) extracellular ves-
icles released from almost all types of cells, they can contain
various bioactive molecules, such as nucleic acids (DNA and
RNA), proteins, and lipids and, thus, can be involved in prox-
imal and distal intercellular communication. Exosomes are
believed to influence immune regulation, tumor invasion, and
cellular degeneration.76 Exosomes and associated proteins
could be a marker of PAH severity. For example, TCTP was
previously identified in a proteomic analysis of outgrowth
EPCs (see above). Ferrer et al.77 found that TCTP was also
localized in extracellular vesicles, blood outgrowth endothelial
cells (BOECs) isolated from patients harboring BMPR2 muta-
tions released more exosomes than those derived from control
subjects in proapoptotic conditions. Co-culture assays demon-
strated that exosomes transferred TCTP from ECs to
PASMCs, suggesting a role for endothelial-derived TCTP in
conferring proliferation and apoptotic resistance. In an experi-
mental model of PAH, rats treated with monocrotaline demon-
strated increased concentrations of TCTP in the lung and
plasma. Circulating TCTP levels were increased in patients
with IPAH compared with control subjects. Based on these
findings, TCTP was proposed as a potential biomarker for
the onset and development of PAH.
De la Cuesta et al.78 performed a transcriptome analysis
of HPASMCs and their extracellular vesicles. A total of
2417 gene transcripts were detected in HPASMC-EVs; 759
of these were enriched compared to their donor cells and
included TGF-beta superfamily ligands, GDGF 11, and
TGF-beta 3; 90 genes were differentially expressed in extra-
cellular vesicles (EVs) from cells treated with TGF-beta
compared to EVs under basal conditions and included
bHLHE40 and paladin. Intercellular communication
between human pulmonary artery endothelial cells
(HPAECs) and HPASMC was shown via CRE-lox technol-
ogy to be mediated by EVs.
Cell free DNA was shown to be increased in experimental
acute thromboembolism.79 The idea of using cell free DNA
as a biomarker for PAH disease severity is in the early stage
of development.
In summary, there is growing interest in the study of
exosomes and cell free DNA in clinical studies of PAH;
these extracellular components may be of interest as
exploratory endpoints in future studies.
Noninvasive imaging of the PAH lung
CT imaging
There are typical lung parenchymal changes in PAH
that are seen on routine high-resolution CT or CT
pulmonary angiography. Centrilobular ground glass nodu-
larity seen in approximately 40% of patients with IPAH. In
addition, some features are more typical of PVOD may be
seen such as mediastinal lymphadenopathy and interlobu-
lar septal thickening.80 The presence of coexistent parenchy-
mal lung diseases, such as interstitial fibrosis and
emphysema, even if mild, can have a large effect on patient
outcome.81
Advances in CT image acquisition, reconstruction, and
post-processing have led to an increasing number of quan-
titative features that can be used to define the pulmonary
vascular architecture, provide quantitative measures of pul-
monary vascular remodeling, and monitor response to
therapeutic intervention. In a proof of concept study,
Rahaghi et al.82 measured changes in pulmonary vascular
caliber and volume in response to inhaled nitric oxide on
clinically available non-contrast CT scans. Hajian et al.83
applied a similar approach to quantify pulmonary blood
vessel volume from CT data obtained in subjects with pul-
monary hypertension and chronic obstructive pulmonary
disease (COPD) before and after inhaled nitric oxide. In
the future, these types of approaches could be deployed to
examine the therapeutic response to anti-proliferative dis-
ease modifying therapies. Further work is required to evalu-
ate the repeatability of these measurements and to
understand what constitutes a meaningful change. The ves-
sels detected by CT (>0.5mm in diameter) are typically
larger than the vessels most affected by PVD, but improve-
ments in analytical methods and the use of artificial intelli-
gence to evaluate CT scans from PAH patients may be on
the horizon and might provide more detailed information
about disease modification.
PET imaging
Zhao et al.84 performed dynamic PET imaging with 18FDG
ligand with kinetic analysis in 20 patients with PAH. The
lung parenchymal uptake was increased in the PAH group
compared to controls (IPAH, n¼ 18, FDG score:
3.27 1.22; connective tissue disease APAH, n¼ 2, FDG
score: 5.07 and 7.11; controls FDG score: 2.02 0.71;
p< 0.05). Compartment analysis confirmed increased lung
glucose metabolism in IPAH. Lung 18FDG uptake and
metabolism varied within the IPAH population and within
the lungs of individual patients, consistent with the recog-
nized heterogeneity of vascular pathology in this disease.
The monocrotaline rat PAH model also showed increased
lung 18FDG uptake, which was reduced along with improve-
ments in vascular pathology after treatment with dichloroa-
cetate and two tyrosine kinase inhibitors, imatinib and
sunitinib. Hyperproliferative pulmonary vascular fibroblasts
isolated from IPAH patients exhibited upregulated glycolytic
gene expression, along with increased cellular 18FDG uptake;
both were reduced by dichloroacetate and imatinib.
In a series of 30 patients, Saygin et al.85 found that right
ventricular end-diastolic and end-systolic volumes, right
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ventricular ejection fraction, and right ventricular FDG
uptake by PET were significantly different between PH
and healthy controls and strongly correlated with plasma
NT-proBNP levels. In addition, lung standardized uptake
value (SUV) was also found to be significantly higher in
participants with PH than healthy controls. However, lung
SUV did not show any significant correlations with NT-
proBNP levels.
However, Ruiter et al.86 did not find a significant increase
in 18FDG uptake in the lungs of PAH subjects, and 18FDG
uptake in the lungs did not correlate with various param-
eters of disease severity, thus raising concerns regarding the
utility of 18FDG-PET for the evaluation of this patient
population.
Due to the relatively low signal-to-noise ratio, and het-
erogeneity of FDG uptake in PAH subjects, alternative ima-
ging agents to evaluate PAH as a proliferative disease have
been sought.
Ashek et al.87 performed dynamic 18FLT PET in eight
patients with IPAH and applied in-depth kinetic analysis
with a reversible two-compartment 4k model. There was a
significantly increased lung 18FLT phosphorylation (k3) in
patients with IPAH compared with non-PAH controls
(0.086 0.034 versus 0.054 0.009min-1; p< 0.05). There
was heterogeneity in the lung 18FLT signal both between
patients with IPAH and within the lungs of each patient,
compatible with histopathologic reports of lungs from
patients with IPAH. Consistent with 18FLT PET data, thy-
midine kinase 1 (TK1) expression was evident in the remo-
deled vessels in IPAH patient lung. In addition,
hyperproliferative pulmonary vascular fibroblasts isolated
from patients with IPAH exhibited upregulated expression
of TK1 and the thymidine transporter, equilibrative nucleoside
transporter 1. In the monocrotaline and Sugen hypoxia rat
PAH models, increased lung 18FLT uptake was strongly asso-
ciated with peripheral pulmonary vascular muscularization
and the proliferation marker, Ki-67 score, together with prom-
inent TK1 expression in remodeled vessels. The lung 18FLT
uptake was attenuated by two antiproliferative treatments:
dichloroacetate and the tyrosine kinase inhibitor, imatinib.
More recently, evidence for macrophage-mediated
inflammation was demonstrated in PAH subjects using
(68)Ga-2-(p-isothiocyanatobenzyl)-1,4,7-triazacyclononane-
1,4,7-triacetic acid (NOTA) mannosylated human serum
albumin ((68)Ga-NOTA-MSA) PET imaging: pulmonary
uptake of (68)Ga-NOTA-MSA was significantly higher in
patients with PAH than normal subjects or than those with
pulmonary hypertension due to left heart disease.88 Other
PET-based imaging agents, such as agents that quantify
adrenomedullin receptors in the lung, have been proposed
but remain in the nascent stage of development.89
In summary, PET imaging to evaluate underlying pro-
cesses implicated in PAH pulmonary vascular remodeling
and inflammation holds some promise, but the studies
thus far have been small with mixed results. Issues related
to mechanism of action under study, signal-to-noise ratios,
availability of imaging agents, and PET imagers need to be
considered if this technology is to be implemented in larger
clinical studies of PAH.
Xenon MRI
Xenon MRI has recently been applied to evaluate patients
with PVD.
Wang et al.90 compared 129 Xenon MRI images and
dynamic spectroscopy in healthy volunteers (n¼ 23) and
patients with COPD (n¼ 8), idiopathic pulmonary fibrosis
(IPF) (n¼ 12), left heart failure (LHF) (n¼ 6), and PAH
(n¼ 10). For each patient, three-dimensional maps were
generated to depict ventilation, barrier uptake (129Xe dis-
solved in interstitial tissue), and red blood cell (RBC) trans-
fer (129Xe dissolved in RBCs). Dynamic 129Xe
spectroscopy was used to quantify cardiogenic oscillations
in the RBC signal amplitude and frequency shift. Compared
with healthy volunteers, all patient groups exhibited
decreased ventilation and RBC transfer (both p 0.01).
Patients with COPD demonstrated more ventilation and
barrier defects compared with all other groups (both
p 0.02). In contrast, IPF patients demonstrated elevated
barrier uptake compared with all other groups (p 0.007)
and increased RBC amplitude and shift oscillations com-
pared with healthy volunteers (p¼ 0.007 and p 0.01,
respectively). Patients with COPD and PAH both exhibited
decreased RBC amplitude oscillations (p¼ 0.02 and
p¼ 0.005, respectively) compared with healthy volunteers.
LHF was distinguishable from PAH by enhanced RBC
amplitude oscillations (p¼ 0.01). 129Xe red blood cell che-
mical shift to measure pulmonary blood oxygenation in vivo
has been shown to be feasible.90 There is also potential to
estimate pulmonary interstitial thickness which is of parti-
cular interest in interstitial lung disease and associated vas-
cular disease.91
In summary, RBC amplitude oscillations measured with
Xenon MRI represent a non-invasive physiologically mean-
ingful assessment of localized pulmonary capillary blood
flow and therefore could be a useful parameter to evaluate
the response to therapeutic interventions in PAH subjects.
Noninvasive imaging of the RV
Echocardiography
Echocardiographic parameters that have traditionally been
studied in the PAH population include right atrium (RA)
and RV dimensions, RV fractional area change, tricuspid
annular plane systolic excursion, the left ventricle (LV)
eccentricity index, and presence of a pericardial effusion.
In particular, an enlarged RA and presence of a pericardial
effusion are risk factors that contribute to poor prognosis
based on the 2015 ESC/ERS guidelines. The LV eccentricity
index captures the change in morphology of the LV in the
setting of PAH. As pulmonary pressures increase, the
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interventricular septum tends to flatten and bulge into the
LV. This change can be expressed as the ratio of the minor
axis of the LV parallel to the septum (D2) divided by the
minor axis perpendicular to the septum (D1).91 As the
septum flattens and bulges into the LV, the LV eccentricity
index increases. This parameter as well as the RV area/LV
area ratio were found to be useful in early clinical trials of
endothelin receptor antagonists.92
In 1996, Dr. Tei reported an index of RV myocardial
performance that has become known as the Tei Index.93
This index is the ratio of isovolumic contraction and relax-
ation time divided by the RV ejection time. Intuitively one
can appreciate that, in the face of increased afterload due to
pulmonary hypertension (PH), isovolumic contraction and
relaxation times would be increased and RV ejection time
decreased. Thus, the RV Tei Index is elevated in PAH com-
pared to normal subjects.
More recently, it has been shown that changes in the RV
Tei Index correlated with changes in PVR (r¼ 0.706,
p¼ 0.002, n¼ 16).94
There is growing interest in the measurement of RV
strain to evaluate changes in RV function in the setting of
PH. Strain refers to mechanical deformation and can be
measured using the echocardiographic technique of speckle
tracking. With respect to evaluation of RV strain, it can be
measured in three aspects: longitudinal (also referred to as
free wall); circumferential; and radial. Global RV strain, as
well as strain rates (the rate of change of strain), can be
measured. RV free wall strain (RVFWS) appears to be the
most robust measurement. RVFWS measured by echo cor-
related with RVEF measured by CMR (r¼ 0.83, p< 0.005,
n¼ 66). In a multivariate analysis, RVFWS> –14% was
associated with worse outcomes (HR: 4.66, CI: 1.25–17.37,
p¼ 0.022). In a multivariate analysis, the only echo param-
eter associated with a clinical composite endpoint (six hos-
pitalizations and nine deaths) was RVFWS.95
RV global longitudinal peak systolic strain (RV GLS)
was found to correlate with PVR (r¼ –0.549, p< 0.05).96
In a prospective series of subjects with known or sus-
pected PH (n¼ 575, n¼ 300 with WHO group 1 PAH),
RVFWS correlated with functional class, six-minute walk
distance, NT-proBNP, and right heart failure, with HR
1.46 (1.05–2.12) for death per every 6.7% decline in RV
strain. RV strain predicted survival when adjusted for pul-
monary pressure, PVR, and RAP.97
Siddiqui et al.98 found that RV GLS was associated with
hospitalization or death (n¼ 98, HR: 1.54 per 1 SD (5.31),
95% CI: 2.12, p¼ 0.008). In a meta-analysis of 11 studies to
examine RV strain n¼ 1169 PH patients, a 19% reduction in
RVLS had a higher risk of combined endpoint HR 1.22, and
a 22% reduction in RV GLS had a higher risk of all-cause
mortality HR 2.96.99 In another meta-analysis, which exam-
ined 10 published studies (n¼ 1001 of which 76% had
PAH), RV strain when treated as a continuous variable
had a HR of 1.14 (95% CI: 1.11–1.8, p< 0.001) per 1%
change for mortality.100 In the echo substudy of the
IMPRES trial, RV Tei Index improved significantly com-
pared to placebo at week 24 (n¼ 74, Imatinib change from
baseline: 0.11 0.18; placebo 0.5 0.18, p¼ 0.007).101 In
another analysis of the IMPRES echo substudy, right ven-
tricular free wall longitudinal strain (FWLS) and LV global
circumferential strain were measured at baseline, 12 weeks,
and 24 weeks in 68 patients with advanced PAH randomized
to imatinib or placebo. Improvement in PVR at 24 weeks
correlated with a change in RVFWLS (r¼ 0.39, p¼ 0.02,
n¼ 37) and LV global circumferential strain (r¼ 0.61,
p< 0.001, n¼ 36). Using a repeated measure mixed effects
model, the improvement in RVFWS in the imatinib group
corrected for baseline was significant compared to the pla-
cebo group (p¼ 0.03). This analysis included the echo data
from weeks 12 and 24.102 The strain analysis of echo data
from the IMPRES trial was not pre-specified. The interest-
ing results were considered hypothesis generating. The
table 1 summarizes the RFWS data at baseline, 12 weeks,
and 24 weeks.
Various attempts have been made to develop formulae
from echocardiographic parameters that correlate with
PVR measured by right heart catheterization (RHC). For
example, Kasai et al.103 found that TRPG/COLVOT corre-
lated highly with PVR measured at RHC (r¼ 0.807,
p< 0.001). The data were based on echocardiograms of 40
subjects with chronic thromboembolic pulmonary hyperten-
sion (CTEPH), which may or may not be applicable to car-
diopulmonary hemodynamics of subjects with WHO Group
1 PAH. Abbas et al.104 correlated TRV2/TVIRVOT with
PVR from RHC (r¼ 0.79, p< 0.001) in 150 subjects not
restricted to PAH. However, in subjects with a PVR> 6
Wood units, the r value fell to 0.33–0.48. In a retrospective
study of 45 subjects, Sinha et al.105 reported that pulmonary
artery elastance adjusted for hemoglobin correlated with
PVR measured at RHC (r¼ 0.89, p¼ 0.008). The utility of
these formulae to assess the effect of a therapeutic interven-
tion in the setting of a clinical trial is not known.
In summary, measurement of changes in RV Tei Index
and RVFWS correlate with RVEF measured by cMRI as
well as PVR and are likely to provide meaningful informa-
tion with regard to clinical outcomes including survival.
cMRI
Noninvasive imaging is central to assessment of disease
severity and progression in patients with PAH.106 The cur-
rent ERS/ESC guidelines focus assessment on right atrial
area and the presence of pericardial effusion by echocardi-
ography or cMRI; however, indicators of RV performance
have demonstrated relationships to clinical outcomes, such
as mortality, and provide additional information that per-
mits risk stratification and assessment of therapeutic
insertion.107
The SERAPH study was the first study to use MRI-
derived RV mass as a primary endpoint in a PAH trial,
showing regression of RV hypertrophy with sildenafil.108
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More recently, the REPAIR study (https://clinicaltrials.gov/
ct2/show/NCT02310672) used cMRI-derived stroke volume
as a co-primary endpoint along with PVR in a trial assessing
the effect of Macitentan in PAH as the first study to use
cMRI as a primary endpoint in a clinical trial. This study
uses pulmonary arterial forward flow, akin to stroke volume
as the primary endpoint. RV volume and function are sec-
ondary endpoints. A meta-analysis of studies showed the
prognostic value of RV ejection fraction and volume meas-
urements in PAH.109 However, the relative magnitude of
prognostic significance is difficult to compare. Larger indi-
vidual studies have since been published suggesting that
both RV ejection fraction and RV end-systolic volume are
strong predictors of mortality.107 Thresholds for RVEF and
RV end-systolic volume have been described, with prognos-
tic value demonstrated at baseline and follow-up assess-
ments.106 Relatively higher RV volume to mass ratio has
been proposed as an important prognostic marker, and fur-
ther work is warranted to evaluate the significance of RV
mass:volume phenotypes.110 Clinical studies used RV end-
diastolic mass as a primary endpoint to assess treatment
effects as this was shown to be also of prognostic
value.108,111,112
Right atrial volume has been shown to be a prognostic in
PAH,113 and this is reflected in the ESC/ERS guidelines,
further study of the prognostic importance of the RV rela-
tive to the RA, or even incremental value of both chambers
is also warranted.
Studies have shown the prognostic value of the pulsatility
of the proximal pulmonary vasculature, with incremental
prognostic value when added to the RV.114,115 A limitation
is out of plane motion of the main pulmonary artery, and
assessment of the right main pulmonary artery may be more
robust.115 Such parameters may also have sensitivity to the
detection of early PH. In future, 3D dynamic imaging may
provide a superior assessment of the pulsatility of the prox-
imal vasculature.
The use of machine learning may assist with optimizing the
reproducibility of measurements made of cMRI and maximiz-
ing the prognostic value. Machine learning using convolu-
tional neural networks to automate RV contours has shown
promise and automatic mortality prediction from RV motion
has been shown to have strong prognostic value, in compari-
son to human measurements.116,117 In addition, a tensor-
based machine learning approach has been proposed for auto-
matic extraction of disease features in PAH, with diagnostic
and prognostic utility.118 The value of such approaches
require comparison with standard measurements derived by
human observers.
In summary, MRI parameters of RV function are well
suited to use in clinical studies of PAH as potential bio-
markers of response to therapeutic interventions. Because
these studies are non-invasive, may be performed on scan-
ners that are widely available, have parameters which are
reproduceable, and correlate with clinical outcomes, they
could have utility in future clinical studies of PAH.
Artificial intelligence applied to understand-
ing the complexity of PAH pathogenesis
In a prospective observational study of WHO group 1
PAH patients, Sweatt et al.119 measured a circulating prote-
omic panel of 48 cytokines, chemokines, and factors using
multiplex immunoassay. Unsupervised machine learning
(consensus clustering) was applied in two cohorts independ-
ently to classify patients into proteomic immune clusters,
without guidance from clinical features. To identify central
proteins in each cluster, partial correlation network analysis
was performed. Clinical characteristics and outcomes were
subsequently compared across clusters. Four PAH clusters
with distinct proteomic immune profiles were identified in
the discovery cohort. Cluster 2 (n¼ 109) had low cytokine
levels similar to controls. Other clusters had unique sets of
upregulated proteins central to immune networks-cluster 1
(n¼ 58; TNF-related apoptosis-inducing ligand (TRAIL),
C-C motif chemokine ligand 5 (CCL5), CCL7, CCL4,
macrophage migration inhibitory factor (MIF)), cluster 3
(n¼ 77; IL-12, IL-17, IL-10, IL-7, VEGF), and cluster 4
(n¼ 37; IL-8, IL-4, PDGF-beta, IL-6, CCL11).
Demographics, PAH clinical subtypes, comorbidities, and
medications were similar across clusters. Noninvasive and
hemodynamic surrogates of clinical risk identified cluster 1
as high-risk and cluster 3 as low-risk groups. Five-year
transplant-free survival rates were unfavorable for cluster
1 (47.6%; 95% CI: 35.4–64.1%) and favorable for cluster
3 (82.4%; 95% CI: 72.0–94.3%; across-cluster p< 0.001).
Findings were replicated in a validation cohort, where
machine learning classified four immune clusters with com-
parable proteomic, clinical, and prognostic features.
In summary, the use of artificial intelligence to analyze
complex datasets and to identify novel regulated pathways
predictive of outcomes could also be leveraged to identify
biomarkers of therapeutic response in clinical trials.
Publicly available databases
Tissue and blood repositories available for research
There are several repositories established for biological sam-
ples from PAH subjects. Most involve blood samples. One
repository, the Pulmonary Hypertension Breakthrough
Initiative (PHBI) sponsored by the NHLBI, has stored
lung tissue preserved in various formats. Researchers
affiliated with academic institutions may access the PHBI
resources through an application process (phbi.org). The
NIH/NHLBI launched an initiative, ‘‘Redefining
Pulmonary Hypertension through Pulmonary Vascular
Disease Phenomics (PVDOMICS)’’, that aims to augment
the current PH classification based on shared biological fea-
tures. PVDOMICS will enroll 1500 participants with PH
due to various etiologies (WHO Groups 1–5) and healthy
comparators. Enrollees will undergo deep clinical phenotyp-
ing and blood will be acquired for comprehensive omic ana-
lyses that will focus on discovery of molecular-based
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subtypes of PVD through application of high dimensional
model-based clustering methods. In addition to an updated
molecular classification of PVD, the phenomic data gener-
ated will be a rich resource to the broad community of heart
and lung disease investigators.118 In future clinical studies of
PAH subjects, it is hoped that academic centers and
pharmaceutical industry sponsors will continue to collabor-
ate to optimize the use of samples collected for analyses of
biomarkers and translational research toward the common
goal of improving diagnosis, prognosis, and therapies avail-
able for patients with PAH.
Summary and conclusions
There has been extensive work to identify potential bio-
markers for PAH. Omic strategies have been employed to
examine changes at the level of gene and protein expression
as well as changes in miRNAs and metabolic profiles.
Changes in circulating cell subtypes, cell free DNA, and
exosomes have been examined. Most studies attempt to
distinguish PAH from normal control subjects and to iden-
tify prognostic markers. Transcriptomics of lung and
blood/PBMCs suggest some degree of overlap of regulated
networks involved in inflammation and other pathways that
could be useful in evaluating response to future therapies
targeting these networks. An example from the field of
proteomics has been described wherein a panel of nine pro-
teins showed prognostic power independent of the
REVEAL score. There is potential utility of using bio-
markers to predict response to a therapeutic intervention.
However, there is also evidence that local cell type-specific
pathway perturbations occur in PAH lung that are not
easily discernible from analysis of peripheral biomarkers.
Because right ventricular function is closely associated
with prognosis in PAH, imaging the RV with either echo-
cardiography or cMRI is of growing interest. Newer tech-
niques to examine pulmonary vasculature remodeling with
3D CT reconstruction or Xenon MRI have been explored in
small studies. In addition, PET imaging with agents
associated with inflammation and cell proliferation have
been reported. From a regulatory perspective, there are cur-
rently no validated biomarker surrogate endpoints that
meet criteria for use as approvable endpoints in PAH.
Indeed, even NT-proBNP does not meet criteria for use as
a surrogate endpoint based on the EMA guidelines.
Nevertheless, NT-proBNP and potentially other biomarkers
have utility to examine the effects of therapy, as well as use
as prognostic indicators. Finally, there is a growing interest
in the use of artificial intelligence/machine learning with
potential applications to imaging and analyses of large
omic databases.
Take-home message
There is potential utility of using biomarkers to predict
response to a therapeutic intervention and utilize these to
enrich a clinical trial population or use as an endpoint.
A wide variety of genomic, proteomic, and metabolomic
approaches are being proposed and are actively under
consideration.
Right ventricular function is closely associated with prog-
nosis in pulmonary arterial hypertension, leading to a poten-
tial role for imaging the right ventricle with either
echocardiography or cardiac magnetic resonance imaging
as a principal endpoint. Newer techniques to examine pul-
monary vasculature remodeling with 3D computed tomo-
graphic reconstruction or Xenon magnetic resonance
imaging are being explored in small studies. In addition,
positron emission tomography imaging with agents asso-
ciated with inflammation and cell proliferation have been
reported. From a regulatory perspective, there are currently
no validated biomarker surrogate endpoints that meet cri-
teria for use as approvable endpoints in Pulmonary arterial
hypertension. Indeed, even NT-proBNP does not meet cri-
teria for use as a surrogate endpoint based on the European
Medicines Agency guidelines.
Nevertheless, NT-proBNP and potentially other bio-
markers have utility to examine the effects of therapy, help
stratify patient selection pre randomization as well as play-
ing a role as prognostic indicators.
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Table 1. RVFWS from IMPRES echo sub-study.
Time Placebo N Placebo mean Placebo SE Imatinib N Imatinib mean Imatinib SE
Baseline 35 –16 0.8 39 –16.8 1.2
12 weeks 33 –16.3 0.9 29 –18.4 1.5
24 weeks 28 –15.9 1.0 31 –20.1 1.8
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